{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T09:16:56Z","timestamp":1764494216739,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s11845-022-03044-4","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T02:03:36Z","timestamp":1654740216000},"page":"731-739","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Immune response to COVID-19 vaccination in a population with and without a previous SARS-CoV-2 infection"],"prefix":"10.1007","volume":"192","author":[{"given":"Mary","family":"Duro","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8604-4594","authenticated-orcid":false,"given":"Cristina","family":"Almeida","sequence":"additional","affiliation":[]},{"given":"In\u00eas","family":"Duro","sequence":"additional","affiliation":[]},{"given":"Am\u00e9lia","family":"Sarmento","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,6,9]]},"reference":[{"key":"3044_CR1","unstructured":"World Health Organization (2020) WHO director-general\u2019s remarks at the media briefing on 2019-nCoV on 11 Feb 2020"},{"issue":"8","key":"3044_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2020.e04743","volume":"6","author":"IM Artika","year":"2020","unstructured":"Artika IM, Dewantari AK, Wiyatno A (2020) Molecular biology of coronaviruses: current knowledge. Heliyon 6(8):e04743. https:\/\/doi.org\/10.1016\/j.heliyon.2020.e04743","journal-title":"Heliyon"},{"key":"3044_CR3","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3389\/fmicb.2020.00298","volume":"11","author":"N Wang","year":"2020","unstructured":"Wang N et al (2020) Subunit vaccines against emerging pathogenic human coronaviruses. Front Microbiol 11:298. https:\/\/doi.org\/10.3389\/fmicb.2020.00298","journal-title":"Front Microbiol"},{"issue":"3","key":"3044_CR4","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nrmicro2090","volume":"7","author":"L Du","year":"2009","unstructured":"Du L et al (2009) The spike protein of SARS-CoV\u2013a target for vaccine and therapeutic development. Nat Rev Microbiol 7(3):226\u2013236. https:\/\/doi.org\/10.1038\/nrmicro2090","journal-title":"Nat Rev Microbiol"},{"key":"3044_CR5","volume-title":"Origin of SARS-CoV-2, 26 March 2020","author":"O","year":"2020","unstructured":"World Health Organization (2020) Origin of SARS-CoV-2, 26 March 2020, Geneva"},{"issue":"9","key":"3044_CR6","doi-asserted-by":"publisher","first-page":"e514","DOI":"10.1016\/S2665-9913(20)30212-5","volume":"2","author":"S Felsenstein","year":"2020","unstructured":"Felsenstein S, Hedrich CM (2020) COVID-19 in children and young people. The Lancet Rheumatology 2(9):e514\u2013e516. https:\/\/doi.org\/10.1016\/S2665-9913(20)30212-5","journal-title":"The Lancet Rheumatology"},{"key":"3044_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.610300","volume":"11","author":"R Carsetti","year":"2020","unstructured":"Carsetti R et al (2020) Different innate and adaptive immune responses to SARS-CoV-2 infection of asymptomatic, mild, and severe cases. Front Immunol 11:610300. https:\/\/doi.org\/10.3389\/fimmu.2020.610300","journal-title":"Front Immunol"},{"issue":"5","key":"3044_CR8","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.pulmoe.2021.03.008","volume":"27","author":"JL Boechat","year":"2021","unstructured":"Boechat JL et al (2021) The immune response to SARS-CoV-2 and COVID-19 immunopathology - current perspectives. Pulmonology 27(5):423\u2013437. https:\/\/doi.org\/10.1016\/j.pulmoe.2021.03.008","journal-title":"Pulmonology"},{"key":"3044_CR9","doi-asserted-by":"publisher","unstructured":"Grifoni A et al (2020) Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 Disease and unexposed individuals. Cell\u00a0181(7):1489\u20131501 e15. https:\/\/doi.org\/10.1016\/j.cell.2020.05.015","DOI":"10.1016\/j.cell.2020.05.015"},{"issue":"1","key":"3044_CR10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/imm.13262","volume":"162","author":"SM Toor","year":"2021","unstructured":"Toor SM et al (2021) T-cell responses and therapies against SARS-CoV-2 infection. Immunology 162(1):30\u201343. https:\/\/doi.org\/10.1111\/imm.13262","journal-title":"Immunology"},{"key":"3044_CR11","doi-asserted-by":"publisher","unstructured":"Duro M et al (2021) Pre-vaccination immune response to COVID-19 in a population in Northeast Portugal. Ir J Med Sci 1\u20138.\u00a0https:\/\/doi.org\/10.1007\/s11845-021-02799-6","DOI":"10.1007\/s11845-021-02799-6"},{"key":"3044_CR12","doi-asserted-by":"publisher","unstructured":"Choe PG et al (2021) Waning antibody responses in asymptomatic and symptomatic SARS-CoV-2 infection. Emerg Infect Dis\u00a027(1). https:\/\/doi.org\/10.3201\/eid2701.203515","DOI":"10.3201\/eid2701.203515"},{"issue":"8","key":"3044_CR13","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1099\/jgv.0.001439","volume":"101","author":"P Kellam","year":"2020","unstructured":"Kellam P, Barclay W (2020) The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. J Gen Virol 101(8):791\u2013797. https:\/\/doi.org\/10.1099\/jgv.0.001439","journal-title":"J Gen Virol"},{"issue":"12","key":"3044_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0244126","volume":"15","author":"N Post","year":"2020","unstructured":"Post N et al (2020) Antibody response to SARS-CoV-2 infection in humans: a systematic review. PLoS ONE 15(12):e0244126. https:\/\/doi.org\/10.1371\/journal.pone.0244126","journal-title":"PLoS ONE"},{"issue":"1","key":"3044_CR15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1440-1843.2006.00783.x","volume":"11","author":"H Mo","year":"2006","unstructured":"Mo H et al (2006) Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance. Respirology 11(1):49\u201353. https:\/\/doi.org\/10.1111\/j.1440-1843.2006.00783.x","journal-title":"Respirology"},{"issue":"8","key":"3044_CR16","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41577-021-00578-z","volume":"21","author":"M Sadarangani","year":"2021","unstructured":"Sadarangani M, Marchant A, Kollmann TR (2021) Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat Rev Immunol 21(8):475\u2013484. https:\/\/doi.org\/10.1038\/s41577-021-00578-z","journal-title":"Nat Rev Immunol"},{"issue":"20","key":"3044_CR17","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1056\/NEJMc2104281","volume":"384","author":"N Barda","year":"2021","unstructured":"Barda N, Dagan N, Balicer RD (2021) BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting. Reply N Engl J Med 384(20):1970. https:\/\/doi.org\/10.1056\/NEJMc2104281","journal-title":"Reply N Engl J Med"},{"issue":"15","key":"3044_CR18","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","volume":"384","author":"N Dagan","year":"2021","unstructured":"Dagan N et al (2021) BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 384(15):1412\u20131423. https:\/\/doi.org\/10.1056\/NEJMoa2101765","journal-title":"N Engl J Med"},{"issue":"20","key":"3044_CR19","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1056\/NEJMc2104281","volume":"384","author":"S Roest","year":"2021","unstructured":"Roest S, Hoek RAS, Manintveld OC (2021) BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 384(20):1968\u20131970. https:\/\/doi.org\/10.1056\/NEJMc2104281","journal-title":"N Engl J Med"},{"key":"3044_CR20","doi-asserted-by":"publisher","unstructured":"Thompson MG et al (2021) Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers - eight U.S. locations, December 2020-March 2021. MMWR Morb Mortal Wkly Rep 70(13):495\u2013500. https:\/\/doi.org\/10.15585\/mmwr.mm7013e3","DOI":"10.15585\/mmwr.mm7013e3"},{"issue":"4","key":"3044_CR21","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1053\/j.ajkd.2021.06.002","volume":"78","author":"JJ Broseta","year":"2021","unstructured":"Broseta JJ et al (2021) Humoral and cellular responses to mRNA-1273 and BNT162b2 SARS-CoV-2 vaccines administered to hemodialysis patients. Am J Kidney Dis 78(4):571\u2013581. https:\/\/doi.org\/10.1053\/j.ajkd.2021.06.002","journal-title":"Am J Kidney Dis"},{"issue":"15","key":"3044_CR22","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1056\/NEJMoa2110362","volume":"385","author":"MG Thompson","year":"2021","unstructured":"Thompson MG et al (2021) Effectiveness of COVID-19 vaccines in ambulatory and inpatient care settings. N Engl J Med 385(15):1355\u20131371. https:\/\/doi.org\/10.1056\/NEJMoa2110362","journal-title":"N Engl J Med"},{"issue":"10275","key":"3044_CR23","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","volume":"397","author":"DY Logunov","year":"2021","unstructured":"Logunov DY et al (2021) Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 397(10275):671\u2013681. https:\/\/doi.org\/10.1016\/S0140-6736(21)00234-8","journal-title":"Lancet"},{"issue":"27","key":"3044_CR24","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP et al (2020) Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 383(27):2603\u20132615. https:\/\/doi.org\/10.1056\/NEJMoa2034577","journal-title":"N Engl J Med"},{"key":"3044_CR25","doi-asserted-by":"publisher","unstructured":"Wang H et al (2020) Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell 182(3):713\u2013721 e9.\u00a0https:\/\/doi.org\/10.1016\/j.cell.2020.06.008","DOI":"10.1016\/j.cell.2020.06.008"},{"issue":"1","key":"3044_CR26","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1038\/s41467-021-24285-4","volume":"12","author":"P Jalkanen","year":"2021","unstructured":"Jalkanen P et al (2021) COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. Nat Commun 12(1):3991. https:\/\/doi.org\/10.1038\/s41467-021-24285-4","journal-title":"Nat Commun"},{"issue":"1","key":"3044_CR27","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1080\/22221751.2021.1969291","volume":"10","author":"XN Li","year":"2021","unstructured":"Li XN et al (2021) Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study. Emerg Microbes Infect 10(1):1751\u20131759. https:\/\/doi.org\/10.1080\/22221751.2021.1969291","journal-title":"Emerg Microbes Infect"},{"key":"3044_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2021.104962","volume":"143","author":"M Bongiovanni","year":"2021","unstructured":"Bongiovanni M et al (2021) Evaluation of the immune response to COVID-19 vaccine mRNA BNT162b2 and correlation with previous COVID-19 infection. J Clin Virol 143:104962. https:\/\/doi.org\/10.1016\/j.jcv.2021.104962","journal-title":"J Clin Virol"},{"key":"3044_CR29","doi-asserted-by":"publisher","unstructured":"Psichogiou M et al (2021) Comparative immunogenicity of BNT162b2 mRNA vaccine with natural SARS-CoV-2 infection. Vaccines (Basel)\u00a09(9).\u00a0https:\/\/doi.org\/10.3390\/vaccines9091017","DOI":"10.3390\/vaccines9091017"},{"issue":"9","key":"3044_CR30","doi-asserted-by":"publisher","first-page":"e544","DOI":"10.1016\/S2666-7568(21)00168-9","volume":"2","author":"G Tut","year":"2021","unstructured":"Tut G et al (2021) Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study. The Lancet Healthy Longevity 2(9):e544\u2013e553","journal-title":"The Lancet Healthy Longevity"},{"issue":"8","key":"3044_CR31","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.ccell.2021.06.002","volume":"39","author":"A Thakkar","year":"2021","unstructured":"Thakkar A et al (2021) Seroconversion rates following COVID-19 vaccination amongst patients with cancer. Cancer Cell 39(8):1081\u20131090.e2. https:\/\/doi.org\/10.1016\/j.ccell.2021.06.002","journal-title":"Cancer Cell"},{"key":"3044_CR32","doi-asserted-by":"publisher","unstructured":"Thakkar A et al (2021) Seroconversion rates following COVID-19 vaccination amongst patients with malignant disease-the impact of diagnosis and cancer-directed therapies. https:\/\/doi.org\/10.1101\/2021.05.07.21256824","DOI":"10.1101\/2021.05.07.21256824"},{"key":"3044_CR33","doi-asserted-by":"crossref","unstructured":"Negahdaripour M et al (2021) Administration of COVID-19 vaccines in immunocompromisedpatients. Int Immunol 108021","DOI":"10.1016\/j.intimp.2021.108021"},{"key":"3044_CR34","doi-asserted-by":"publisher","unstructured":"Zimmermann P, Curtis N (2019) Factors that influence the immune response to vaccination. Clin Microbiol Rev 32(2).\u00a0https:\/\/doi.org\/10.1128\/CMR.00084-18","DOI":"10.1128\/CMR.00084-18"},{"issue":"8","key":"3044_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells10081952","volume":"10","author":"A Tretyn","year":"1952","unstructured":"Tretyn A et al (1952) (2021) Differences in the concentration of anti-sARS-CoV-2 IgG antibodies post-COVID-19 recovery or post-vaccination. Cells 10(8), 1952:1\u201316. https:\/\/doi.org\/10.3390\/cells10081952","journal-title":"Cells"},{"issue":"1","key":"3044_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-26479-2","volume":"12","author":"J Wei","year":"2021","unstructured":"Wei J et al (2021) Anti-spike antibody response to natural SARS-CoV-2 infection in the general population. Nat Commun 12(1):1\u201312","journal-title":"Nat Commun"},{"issue":"6","key":"3044_CR37","doi-asserted-by":"publisher","first-page":"2100096","DOI":"10.2807\/1560-7917","volume":"26","author":"KA Jabal","year":"2021","unstructured":"Jabal KA et al (2021) Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021. Eurosurveillance 26(6):2100096. https:\/\/doi.org\/10.2807\/1560-7917","journal-title":"Eurosurveillance"},{"issue":"5","key":"3044_CR38","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1002\/jmv.26863","volume":"93","author":"G Bauer","year":"2021","unstructured":"Bauer G et al (2021) The challenge of avidity determination in SARS-CoV-2 serology. J Med Virol 93(5):3092\u20133104","journal-title":"J Med Virol"},{"key":"3044_CR39","doi-asserted-by":"crossref","unstructured":"Levin EG et al (2021) Waning immune humoral response to BNT162b2 covid-19 vaccine over 6 months. N Eng J Med","DOI":"10.1056\/NEJMoa2114583"},{"issue":"9","key":"3044_CR40","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1038\/s41564-021-00947-3","volume":"6","author":"J Wei","year":"2021","unstructured":"Wei J et al (2021) Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. Nat Microbiol 6(9):1140\u20131149","journal-title":"Nat Microbiol"},{"key":"3044_CR41","doi-asserted-by":"publisher","unstructured":"Lo Sasso B et al (2021) Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine. Diagnostics (Basel) 11(7). https:\/\/doi.org\/10.3390\/diagnostics11071135","DOI":"10.3390\/diagnostics11071135"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-022-03044-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-022-03044-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-022-03044-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,2]],"date-time":"2023-04-02T17:05:12Z","timestamp":1680455112000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-022-03044-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,9]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["3044"],"URL":"https:\/\/doi.org\/10.1007\/s11845-022-03044-4","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"type":"print","value":"0021-1265"},{"type":"electronic","value":"1863-4362"}],"subject":[],"published":{"date-parts":[[2022,6,9]]},"assertion":[{"value":"20 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed written consent was obtained from all participants before the collection of any data regarding the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors accept the terms and conditions of the editorial for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}